Source comparison
Tesamorelin + Ipamorelin Blend Side Effects: Research Comparison
The table below summarizes the most commonly documented tesamorelin + ipamorelin blend side effects across peer-reviewed research, comparing incidence rates, typical onset timing, and resolution patterns. This comparison helps researchers anticipate adverse ev
This comparison does not assign a generated winner or score.
- The table below summarizes the most commonly documented tesamorelin + ipamorelin blend side effects across peer-reviewed research, comparing incidence rates, typical onset timing, and resolution patterns. This comparison helps researchers anticipate adverse event profiles during protocol design.
- Injection site reactions (erythema, swelling, pruritus)
- 40–65%
- First injection onward
- 24–72 hours per injection; chronic reactions rare after week 8
- Rotate sites across 6+ locations; use reconstitution volumes >1mL; reduce benzyl alcohol <0.7%
- Expected and self-limiting; does not predict long-term tolerance issues
- Transient hyperglycemia or altered glucose tolerance
- 18–28%
- Weeks 2–8
- Normalizes by weeks 12–16 despite continued use
- Monitor fasting glucose weekly; avoid high-GI meals within 4 hours post-injection
- Dose-dependent; significant only in subjects with pre-existing insulin resistance
- Joint discomfort or arthralgias
- 15–22%
- Weeks 3–6
- Resolves by weeks 8–12
- Gradual titration; maintain hydration >2.5L/day
- Non-inflammatory; reflects IGF-1-mediated tissue adaptation
- Peripheral edema (hands, feet, periorbital)
- 12–18%
- Weeks 4–8
- Resolves by weeks 10–14
- Reduce sodium intake <2300mg/day; elevate extremities; monitor fluid balance
- GH-mediated sodium retention; transient and not pathological
- Lipodystrophy redistribution (visceral fat reduction)
- 8–15%
- Weeks 6–12
- Progressive; sustained throughout administration
- Not a mitigation target. This is a therapeutic outcome; monitor waist circumference
- Desired effect in metabolic research; can manifest before weight loss
- Headache or transient dizziness
- 6–12%
- Variable; often post-injection within 2–4 hours
- Resolves within 6–12 hours
- Administer in evening; avoid large meals immediately prior
- Likely GH-mediated blood flow changes; benign